Current Vaccine Shortages & Delays

This web page contains the latest national information about vaccine supplies and provides guidance to healthcare providers who are facing vaccine shortages or delays.

*Note: Only those vaccines included on the recommended childhood, adolescent, and adult immunization schedules for routine vaccination are included in this update.

Procuring Needles and Syringes

How to respond to challenges in procuring sufficient quantities of needles or needle/syringe sets to meet the demand for influenza and other routine vaccinations.

Chart of Vaccines* in Delay or Shortage

National Vaccine Supply Shortages

Vaccine shortages
Vaccine Shortage Temporary Change From Routine Recommendation
Diphtheria, Tetanus, & Pertussis (DTaP) No1
Haemophilus influenzae type B (Hib) No
Hepatitis A No
Hepatitis B No
Human Papillomavirus (HPV) No
Inactivated Polio (IPV) No
Influenza No2 See current information about influenza
Measles, Mumps, & Rubella (MMR) No
Meningococcal Conjugated (MCV4) No
Pneumococcal Conjugated (PCV) No
Pneumococcal Polysaccharide (PPV) No
Respiratory syncytial virus (RSV) Yes3 Yes. See Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab
Rotavirus No
Serogroup B Meningococcal (MenB) No
Td and Tdap Yes4 CDC guidance is available here
Varicella No
Zoster No
1Sanofi Pasteur has decided to discontinue production and distribution of Diphtheria and Tetanus Toxoids Adsorbed® (DT) and is withdrawing its licenses in all countries. The last lot was manufactured in October 2020 with an expiry date of April 2023. Sanofi expects to exhaust available supply by the end of 2022.
2Supply of Sanofi’s Flublok vaccine for the 2023-24 season is reduced from the original supply plan. Impacted customers have been or are being contacted by the manufacturer and offered doses of Fluzone QIV influenza vaccine or Fluzone High Dose influenza vaccine.  The manufacturer has reported that there are sufficient supplies of both of these vaccines available to address the reduction in the supply of Flublok for the 2023-24 season.
3In the context of a limited supply of nirsevimab during the 2023-2024 RSV season, CDC initially recommended prioritizing available 100mg doses. Given the recent increase in supply of nirsevimab, CDC advises providers to immunize infants as quickly as possible in accordance with ACIP recommendations rather than reserving doses for infants born later in the RSV season. Although the supply of nirsevimab has increased, available supply may continue to vary locally and by healthcare facility. Providers who continue to have limited supply should prioritize nirsevimab to protect infants at the highest risk for severe RSV disease
4MassBiologics has discontinued production of their Td vaccine, TdVax.TM Grifols, who is the exclusive distributor for TdVaxTM expects to have product available through approximately June 2024.   Sanofi, who manufacturers Tenivac,® is taking steps to augment their available supply of Td for the US.  However, it is anticipated that the supply of Td vaccine in the US market will be constrained during 2024.  Temporary ordering controls have been put into place in the public and private sectors to help manage the gap in supply.  Tdap vaccine is available from both US-licensed manufacturers without supply constraints at this time.

Why are there vaccine shortages?

In the United States shortages of many vaccines in the recommended childhood immunization schedule occurred in the past. Some of these shortages were widespread while others were localized. Reasons for these shortages were multi-factorial and included companies leaving the vaccine market, manufacturing or production problems, and insufficient stockpiles. Consequently, some shortages were only specific to one manufacturer.

Shortages of several of these vaccines necessitated temporary changes in recommendations for their use. During that period, summary information about the shortages including projected duration and recommendations for temporary changes in the childhood immunization schedule were provided.

Who can I contact to answer my questions?

  • Questions including those dealing with changes in child care and school requirements necessitated by vaccine supply problems when they occur can be answered by State Health Department immunization programs.
  • General immunization questions can be answered by
    The CDC Contact Center at 1-800-CDC-INFO
    (1-800-232-4636) English and Español

How often will this information be updated?

This vaccines shortages page is updated as needed. If you wish to be notified when it is updated, please use enter your email on this page in the box labeled “Get Email Updates”.

The FDA’s web page on Biological Product Shortages provides additional information regarding regulatory issues related to vaccine supply.

Acronyms and Abbreviations

Those acronyms and abbrevations not already spelled out above include

  • AAFP – American Academy of Family Physicians
  • AAP – American Academy of Pediatrics
  • ACIP – Advisory Committee on Immunization Practices
  • CDC – Centers for Disease Control and Prevention
  • FDA – Food and Drug Administration
  • GAO – United States General Accounting Office
  • GSK – GlaxoSmithKline
  • MMRV – Measles, Mumps, Rubella, and Varicella combination vaccine
  • MMWR – Morbidity and Mortality Weekly Report
  • NCIRD – National Center for Immunization and Respiratory Diseases
  • TTY – teletypewriter
  • Other acronyms

Related Information